A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancer - A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancer

Start Date17 May 2016

Sponsor / Collaborator-

JPRN-UMIN000022082

/ CompletedPhase 1IIT

Start Date01 Apr 2016

Sponsor / Collaborator

Yamaguchi University

100 Clinical Results associated with Agatolimod

100 Translational Medicine associated with Agatolimod

100 Patents (Medical) associated with Agatolimod

255

Literatures (Medical) associated with Agatolimod

01 Feb 2025·IMMUNOLOGY

IRF5 Controls Plasma Cell Generation and Antibody Production via Distinct Mechanisms Depending on the Antigenic Trigger

Article

Author: Lapan, Margaret ; Battaglia, Jenna ; Matta, Bharati ; Barnes, Betsy J. ; Sharma, Vinay

ABSTRACT:

Elevated levels of serum autoantibodies are a hallmark of systemic lupus erythematosus (SLE) and are produced by plasma cells in response to a variety of antigenic triggers. In SLE, the triggers are complex and may include both T cell‐dependent/‐independent and TLR‐dependent/‐independent mechanisms of immune activation, which ultimately contributes to the significant immune dysregulation seen in patients at the level of cytokine production and cellular activation (B cells, T cells, dendritic cells, neutrophils and macrophages). Interferon regulatory factor 5 (IRF5) has been identified as an autoimmune susceptibility gene and polymorphisms in IRF5 associate with altered expression and hyper‐activation in distinct SLE immune cell subsets. To gain further insight into the mechanisms that drive IRF5‐mediated SLE immune activation, we characterised wild‐type (WT) and Irf5−/− Balb/c mice in response to immunisation. WT and Irf5−/− Balb/c mice were immunised to activate various signalling pathways in vivo followed by systemic immunophenotyping and detection of antibody production by multi‐colour flow cytometry and ELISPOT. We identified two pathways, TLR9‐dependent and T cell‐dependent that resulted in IRF5 cell type‐specific function. Immunisation with either CpG‐B + Alum or NP‐KLH + Alum but not with R848 + Alum, NP‐LPS + Alum or NP‐Ficoll+Alum resulted in decreased plasma cell generation and reduced antibody production in Irf5−/− mice. Notably, the mechanism(s) leading to this downstream phenotype was distinct. In CpG‐B + Alum immunised mice, we found reduced activation of plasmacytoid dendritic cells, resulting in reduced IFNα and IL6 production in Irf5−/− mice. Conversely, mice immunised with NP‐KLH + Alum had reduced numbers of T follicular helper cells and germinal centre B cells with reduced expression of Bcl6 in Irf5−/− mice. Moreover, T follicular helper cells from Irf5−/− mice were functionally defective. Even though the downstream phenotype of reduced antibody production in Irf5−/− mice was conserved between T cell‐dependent and TLR9‐dependent immunisation, the mechanisms leading to this phenotype were antigen‐ and cell type‐specific.

01 Dec 2024·JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY

Zinc deficiency impairs the development of human regulatory B cells from purified B cells

Article

Author: Fischer, Henrike J ; Fischer, Henrike J. ; Bennstein, Sabrina B ; Puppa, Mary-Ann ; Bennstein, Sabrina B. ; Rink, Lothar

Zinc is a vital trace element, important for many different immune processes and adequate functionality. B cell development is known to be dependent on sufficient zinc supply. Recently a regulatory B cell (Breg) population has been identified, as CD19⁺IL-10⁺ B cells, able to regulate immune responses by secretion of anti-inflammatory cytokines, such as IL-10. Due to their promotion of an anti-inflammatory milieu, Bregs could reduce or might even prevent excessive pro-inflammatory responses. Hence, having and maintaining Bregs could be interesting for patients suffering from allergies, asthma, and autoimmune diseases. Therefore, understanding Breg generation, required signaling, and their developmental requirements are important. Since our group could previously show that zinc is important for regulatory T cells, we aimed to determine the effect of zinc deficiency on Breg development from human peripheral blood CD19⁺ B cells. We observed highest Breg generation with a combined stimulus of CD40L and the toll like receptor (TLR) ligand, CpG-ODN2006. Using this stimulus, we observed that zinc deficient medium significantly decreased Breg generation from purified B cells. This was not seen in Bregs generated from peripheral blood mononuclear cells (PBMCs) without B cell enrichment suggesting a compensatory mechanism. In line with literature, our data also confirms Bregs develop from CD19⁺ B cells, since total CD19⁺ frequencies remained unchanged, while Breg frequencies varied between stimuli and zinc media conditions. Our study shows for the first time that zinc deficiency significantly impairs Breg development, which provides an important new perspective for clinical applications and therapeutic strategies.

01 Sep 2024·CELLULAR IMMUNOLOGY

Additional use of α-IgM antibodies potentiates CpG ODN2006-induced B cell activation by targeting mainly naïve and marginal zone-like B cells

Article

Author: Capellino, Silvia ; Fleige, Leonie ; Fillatreau, Simon ; Claus, Maren

CpG ODN2006 is widely used as a potent B cell stimulant in vitro and in vivo. However, it shows a deficit in targeting naïve B cells in vitro. In this study, we investigated whether α-IgM can support ODN2006-induced effects on B cells to obtain enhanced activation with focus on different B cell subsets. Our results delineated robust B cell activation, shown by increased activation marker expression and cytokine secretion by each agent alone, and further augmented when used in combination. Interestingly, α-IgM targeted mainly naïve and marginal zone-like B cells, thus complementing the pronounced effects of ODN2006 on memory B cells and achieving optimal activation for all B cell subsets. Taken together, combining ODN2006 and α-IgM is beneficial for in vitro activation including all B cell subsets. Furthermore, our results suggest that α-IgM could enhance efficacy of ODN2006 in vivo with further need of investigation.

News (Medical) associated with Agatolimod

11 Jun 2024

·www.prnewswire.com

Carpal Tunnel Syndrome: AAOS Updates Clinical Practice Guideline

Latest evidence-based recommendations focused on long-term benefits to help orthopaedic surgeons, physicians and patients determine best treatment approach ROSEMONT, Ill., June 11, 2024 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) issued an update to the Clinical Practice Guideline (CPG) for Management of Carpal Tunnel Syndrome (CTS), which replaces the previous edition from 2016. The guideline was developed to address the diagnosis and treatment of adult patients 18 years of age and older, presenting with complaints that may be attributed to CTS. The updated guideline is streamlined to focus on the long-term benefits of CTS treatment. To view the full guideline, click here. "While the 2016 guideline covered several recommendations for the short-term effects of CTS treatment, our workgroup chose to focus on long-term patient outcomes as shifts in healthcare require a focus on cost-effective, high-quality and patient-centered care," said Lauren Shapiro, MD, co-chair of the guideline development group. "This update provides physicians and patients with clear recommendations to optimize outcomes while minimizing unnecessary interventions." CTS is the most common compressive neuropathy affecting the upper extremity. Symptoms such as pain, numbness and tingling in the hand and forearm can lead to morbidity and lost productivity. According to the National Institutes of Health, in the Medicare patient population alone, the burden of CTS accounts for $2.7 to $4.8 billion annually in the United States. "The CPG was organized to cover workup, treatment and postoperative care of CTS and highlights areas where certain patients can avoid some debatable preoperative treatments (e.g., corticosteroid injections), preoperative tests and postoperative therapies based on the evidence cited in this guideline," said Robin Kamal, MD, FAAOS, co-chair of the guideline development group. CTS Diagnosis The guideline updated the 2016 recommendation to include a strong recommendation on CTS diagnosis, noting that CTS-6, an evaluation tool that accounts for symptoms and disease history, can be used to diagnose CTS. Strong evidence demonstrates that CTS-6 can be used in lieu of the routine use of ultrasonography or a nerve conduction velocity test (NCV) and electromyography (EMG) which can be painful and expensive. Additionally, moderate evidence suggests that MRI and Upper Limb Neurodynamic testing should not be used to diagnose CTS. Treatment The CPG supports the notion that both mini-open and endoscopic carpal tunnel release provide similar long-term outcomes for the treatment of CTS and notes the following recommendations for the treatment of CTS: The use of platelet-rich plasma (PRP) injections – a new addition to the CPG – and corticosteroid injections both demonstrated a lack of long-term benefits in the nonoperative treatment of CTS. Strong evidence showed that local anesthetic alone can be used for carpal tunnel release. Limited evidence suggests that carpal tunnel release may be safely conducted in the office setting. Studies consistently demonstrated that there is no increased risk of complications with higher ratings of patient experience and satisfaction when compared to surgical release in the operating room. Postoperative Care The guideline also includes the following recommendations and option (guidance formulated with either low-quality evidence, no evidence or conflicting evidence) following surgical treatment: Moderate evidence suggests postoperative supervised therapy should not be routinely prescribed after carpal tunnel release. Strong evidence suggests that non-steroidal anti-inflammatory drugs and/or acetaminophen should be used after carpal tunnel release for postoperative pain management. Limited evidence suggests perioperative prophylactic antibiotics are not indicated for the prevention of surgical site infection following carpal tunnel release. Additionally, in the absence of reliable evidence, the guideline notes that it is the opinion of the workgroup that no evidence strongly supports the association between high keyboard use and CTS in the literature. "The recommendations in this CPG highlight areas which are intended for shared decision-making between patients and their physicians and are not meant to be used for insurer determinations," said Dr. Kamal. "It's important for patients to understand the risks, benefits, and costs associated with care in the preoperative (testing), intraoperative (anesthesia) and postoperative (therapy) phases of surgical care. As we continue research on the quality, cost, and patient-centeredness of various treatment approaches, our patients and profession will benefit." Development of this CPG was a collaborative effort between representatives from the American Society for Surgery of the Hand, the American Association for Hand Surgery, the American College of Occupational and Environmental Medicine, the American Society of Hand Therapists, the American College of Radiology, and the American Academy of Physical Medicine and Rehabilitation. CPGs are not meant to be stand-alone documents but rather serve as a point of reference and educational tool for orthopaedic surgeons and healthcare professionals managing patients presenting with complaints which may be attributable to CTS. CPGs recommend accepted approaches to treatment and/or diagnosis and are not intended to be a fixed protocol for treatment or diagnosis. Patient care and treatment should always be based on a clinician's independent medical judgment, giving the individual patient's specific clinical circumstances. The full Clinical Practice Guideline for the Management of Carpal Tunnel Syndrome is intended for reference by orthopaedic surgeons and other physicians, and available through AAOS' OrthoGuidelines website and free mobile app. For more information on the development process for AAOS clinical practice guidelines, please view the Clinical Practice Guideline Methodology. About the AAOS With more than 39,000 members, the American Academy of Orthopaedic Surgeons is the world's largest medical association of musculoskeletal specialists. The AAOS is the trusted leader in advancing musculoskeletal health. It provides the highest quality, most comprehensive education to help orthopaedic surgeons and allied health professionals at every career level to best treat patients in their daily practices. The AAOS is the source for information on bone and joint conditions, treatments and related musculoskeletal healthcare issues; and it leads the healthcare discussion on advancing quality. Follow the AAOS on Facebook, X, LinkedIn and Instagram. SOURCE American Academy of Orthopaedic Surgeons

15 Mar 2024

·www.sciencedaily.com

DNA origami-based vaccines toward safe and highly-effective precision cancer immunotherapy

Researchers have created a DNA origami platform called DoriVac, whose core component is a self-assembling square block-shaped nanostructure. DoriVac vaccines enabled tumor-bearing mice to better control the growth of tumors and to survive significantly longer than control mice. Therapeutic cancer vaccines are a form of immunotherapy in the making that could not only destroy cancer cells in patients, but keep a cancer from coming back and spreading. Multiple therapeutic cancer vaccines are being studied in clinical trials, but despite their promise, they are not routinely used yet by clinical oncologists to treat their patients. The central ingredient of therapeutic cancer vaccines is antigens, which are preferentially produced or newly produced (neoantigens) by tumor cells and enable a patient's immune system to search and destroy the cancerous cells. In most cases, those antigens cannot act alone and need the help of adjuvant molecules that trigger a general alarm signal in immune cells known as antigen-presenting cells (APCs). APCs internalize both antigen and adjuvant molecules and present the antigens to different types of T cells. Those T cells then launch an immediate attack against the tumor, or preserve a longer-lasting memory of the tumor for future defense. A cancer vaccine's effectiveness depends on the level and duration of the "alarm" its adjuvants can ring in APCs. Previously, researchers found that delivering adjuvant and antigen molecules to APCs simultaneously using nanostructures like DNA origami can increase APC activation. However, none of these approaches systematically investigated how the number and nanoscale arrangement of adjuvant molecules affect downstream tumor-directed immunity. Now, a research team at the Wyss Institute at Harvard University, Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), and Korea Institute of Science and Technology (KIST) has created a DNA origami platform called DoriVac, whose core component is a self-assembling square block-shaped nanostructure. To one face of the square block, defined numbers of adjuvant molecules can be attached in highly tunable, nanoprecise patterns, while the opposite face can bind tumor antigens. The study found that molecules of an adjuvant known as CpG spaced exactly 3.5 nanometers apart from each other resulted in the most beneficial stimulation of APCs that induced a highly-desirable pro T cells, including those that kill cancer cells (cytotoxic T cells), those that cause beneficial inflammation (Th-1 polarized T cells), and those that provide a long-term immune memory of the tumor (memory T cells). DoriVac vaccines enabled tumor-bearing mice to better control the growth of tumors and to survive significantly longer than control mice. Importantly, the effects of DoriVac also synergized with those of immune checkpoint inhibitors, which are a highly successful immunotherapy that is already widely used in the clinic. The findings are published in Nature Nanotechnology. "DoriVac's DNA origami vaccine technology merges different nanotechnological capabilities that we have developed over the years with an ever-deepening knowledge about cancer-suppressing immune processes," said Wyss Core Faculty member William Shih, Ph.D., who led the Wyss Institute team together with first-author Yang (Claire) Zeng, M.D., Ph.D.. "We envision that in the future, antigens identified in patients with different types of tumors could be quickly loaded onto prefabricated, adjuvant-containing DNA origami to enable highly effective personalized cancer vaccines that can be paired with FDA-approved checkpoint inhibitors in combination therapies." Shih is also a Professor at HMS and DFCI's Department of Cancer Biology and, as some of the other authors, a member of the NIH-funded cross-institutional "Immuno-engineering to Improve Immunotherapy" (i3) Center based at the Wyss. DNA origami rationale The CpG adjuvant is a synthetic strand of DNA made up of repeated CpG nucleotide motifs that mimic the genetic material from immune cell-invading bacterial and viral pathogens. Like its natural counterparts, CpG adjuvants bind to a "danger receptor" called TLR9 in immune cells, which in turn induces an inflammatory (innate) immune response that works in concert with the antigen-induced (adaptive) immune response. "We knew from previous work that to trigger strong inflammatory responses, TLR9 receptors need to dimerize and aggregate into multimeric complexes binding to multiple CpG molecules. The nanoscale distances between the CpG-binding domains in effective TLR9 assemblies revealed by structural analysis fell right into the range of what we hypothesized we could mirror with DNA origami structures presenting precisely spaced CpG molecules," explained Zeng, who was an Instructor in Medicine at the time of the study and now is a senior scientist at DFCI and Harvard Medical School (HMS). In addition to Shih, Zeng was also mentored on the project by senior authors Ju Hee Ryu, Ph.D., a Principal Researcher at KIST, and Wyss Founding Core Faculty member David Mooney, Ph.D., who also is Professor at Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS), and one of the i3 Center's Principal Investigators. Zeng and the team fabricated DoriVac vaccines in which different numbers of CpG strands were spaced at 2.5, 3.5, 5, or 7 nanometers apart from each other on one face of the square block, and a model antigen was attached to the opposite face. They protected their structures from being degraded in the body using a chemical modification method that Shih's group had developed earlier. When internalized by different types of APCs, including dendritic cells (DCs), which orchestrate tumor-directed T cell responses, the DoriVac vaccines improved the uptake of antigens compared to controls consisting of free antigen molecules. A CpG spacing of 3.5 nanometers produced the strongest and most beneficial responses in APCs, and significantly outperformed a control vaccine containing only free CpG molecules. "We were excited to find that the DoriVac vaccine preferentially induced an immune activation state that supports anti-tumor immunity, which is what researchers generally want to see in a good vaccine," said Zeng. Besides spacing, the numbers of CpG molecules in DoriVac vaccines also mattered. The team tested vaccines containing between 12 to 63 optimally spaced CpG molecules and found that 18 CpG molecules provided the best APC activation. This meant that their approach can also help limit the dosage of CpG molecules and thus minimize commonly observed toxic side effects observed with adjuvants. Gained in (tumor) translation Importantly, these in vitro trends translated to in vivo mouse tumor models. When prophylactically injected under the skin of mice, DoriVac vaccines accumulated in the closest lymph nodes where they stimulated DCs. A vaccine loaded with a melanoma antigen prevented the growth of subsequently injected aggressive melanoma cells. While all control animals had succumbed to the cancer by day 42 of the experiment, DoriVac-protected animals all were alive. DoriVac vaccines also inhibited tumor growth in mice in which the formation of melanoma tumors was already underway, with a 3.5 nanometer spacing of 18 CpG molecules again providing maximum effects on DC and T cells, and the strongest reduction in tumor growth. Next, the team asked whether DoriVac vaccines could also boost immune responses produced by small "neoantigens" emerging in melanoma tumors. Neoantigens are ideal targets because they are exclusively made by tumor cells. However, they often are not very immunogenic themselves, which make highly effective adjuvants an important component in neoantigen vaccines. A DoriVac vaccine customized with four neoantigens enabled the researchers to significantly suppress growth of the tumor in mice that produced the neoantigens. Finally, the researchers asked whether DoriVac could synergize with immune checkpoint therapy, which reactivates T cells that have been silenced in tumors. In mice, the two therapies combined resulted in the total regression of melanoma tumors, and prevented them from growing back when the animals were exposed to the same tumor cells again four months later. The animals had built up an immune memory of the tumor. The team obtained a similar vaccination efficiency in a mouse lymphoma model. "We think that DoriVac's value for determining a sweet spot in adjuvant delivery and enhancing the delivery and effects of coupled antigens can pave the way to more effective clinical cancer vaccines for use in patients with a variety of cancers," said Zeng. The team is currently translating the DoriVac platform toward its clinical application, which is supported by the study's assessment of vaccine distribution and vaccine-directed antibodies in mice, as well as cytokines produced by immune cells in response to the vaccines in vivo. "The DoriVac platform is our first example of how our pursuit of what we call Molecular Robotics -- synthetic bioinspired molecules that have programmable shape and function -- can lead to entirely new and powerful therapeutics. This technology opens an entirely new path for development of designer vaccines with properties tailored to meet specific clinical challenges. We hope to see its rapid translation into the clinic," said Wyss Institute Founding Director Donald Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at HMS and Boston Children's Hospital, and the Hansjörg Wyss Professor of Bioinspired Engineering at SEAS. Other authors on the study are Olivia Young, Christopher Wintersinger, Frances Anastassacos, James MacDonald, Giorgia Isinelli, Maxence Dellacherie, Miguel Sobral, Haiqing Bai, Amanda Graveline, Andyna Vernet, Melinda Sanchez, Kathleen Mulligan, Youngjin Choi, Thomas Ferrante, Derin Keskin, Geoffrey Fell, Donna Neuberg, Cathrine Wu, and Ick Chan Kwon. The study was funded by the Wyss Institute's Validation Project and Institute Project programs, Claudia Adams Barr Program at DFCI, Korean Fund for Regenerative Medicine (award #21A0504L1), Intramural Research Program of KIST (award #2E30840), and National Institutes of Health (under the i3 Center supporting U54 grant (award #CA244726-01).

VaccineImmunotherapyClinical Result

07 Nov 2023

·www.globenewswire.com

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer

DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”) and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma. The new data was presented on November 4, 2023 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) by Marcin Kortylewski, Ph.D. Dr. Kortylewski, Professor of Immuno-Oncology at City of Hope, is the Co-Founder and Senior Scientific Advisor of Duet. Duet is developing novel immunotherapies to overcome treatment-resistant cancers. DUET-102 is a double-stranded antisense oligonucleotide (“ASO”) STAT3 inhibitor linked to a TLR9 immune activator being developed for the treatment of glioma. Glioma is a common type of tumor originating in the glial cells of the brain. Approximately 20,000 patients are diagnosed in the United States annually, with such patients having a 5-year survival rate of less than 7%, reflecting the need for new therapies to combat this disease. Dr. Kortylewski presented the data in a poster titled “Reprograming of Tumor-associated Myeloid Cells by TLR9-targeted STAT3 Antisense Oligonucleotides Sensitizes Malignant Glioma to PD1-specific Immunotherapy”. The featured data shows: Intracranially injected DUET-102 sensitizes malignant glioma to systemic PD-1 blockade, triggering complete rejection of both orthotopic GL261 and PD-1 refractory QPP8 tumors in the majority of treated mice.DUET-102 creates ideal conditions for PD-1 blockade to recruit cancer-killing effector CD8 positive T cells into the tumor by activating intratumoral dendritic cells, M1 macrophages, and microglia, while concurrently reducing immunosuppressive tumor-associated M2 macrophages, resting microglia, and regulatory T cells.DUET-102, as a monotherapy, inhibited tumor growth and extended survival of mice in U251, GL261, and QPP8 models of glioma.DUET-102 was well tolerated and demonstrated unique suitability for intracranial injection, with optimized activity and tolerability in the brain compared to single-stranded ASO designs. Dr. Kortylewski stated, “DUET-102’s unique ability to release immunosuppression around a tumor, creating an environment in which PD-1 blockade can more effectively recruit cancer-killing CD8 positive T cells into glioma without lymphocyte exhaustion, is critical to killing glioma tumor cells. These new data suggest there is compelling potential for significant anti-tumor activity in gliomas utilizing a combination of DUET-102 with PD-1 inhibitors, such as Keytruda (Merck), Opdivo (Bristol-Myers Squibb) and Libtayo (Regeneron). Furthermore, the effectiveness of DUET-102 in releasing immunosuppression may enhance the efficacy of other T-cell based immunotherapies in the context of glioma, including potential combinations of DUET-102 with adoptive cell transfer therapies, such as CAR T-cell therapies.” Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, stated, “These new data clearly show the synergistic potential of combining DUET-102 and PD-1 blockade for the treatment of glioma. There is an acute need for new treatment options for glioma, which have seen no significant advances in the past decade. Our new data demonstrate potent anti-tumor activity in malignant glioma. We are extremely excited about the significant potential of DUET-102 to be a game-changing and much-needed new treatment option for glioma patients.” Dr. Kortylewski added, “DUET-102 is a novel CNS-specific modification of Duet’s lead drug candidate, DUET-101, which is a single-stranded, ASO-based STAT3 inhibitor linked to a TLR9 immune activator being developed for the treatment of advanced solid tumors.” Dr. Horsager further stated, “These new data for DUET-102, taken together with the existing data for DUET-101, further validate the scientific underpinnings and extensive range of opportunities for our proprietary bifunctional oligonucleotide therapeutics. DUET-101 has demonstrated significant activity in a broad array of difficult to treat and genetically distinct cancer models, including metastatic prostate cancer, renal cancer, bladder cancer, and head and neck cancers. We are enthusiastic about the compelling potential of our immuno-oncology pipeline.” About Scopus BioPharma Scopus BioPharma Inc. is a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need. Scopus currently conducts substantially all of its development efforts through Duet BioTherapeutics, its majority owned and controlled subsidiary. The Company may also seek to identify additional compelling technologies for potential acquisition, in-licensing and/or other similar transactions. About Duet BioTherapeutics Duet BioTherapeutics Inc. is a biotechnology company developing novel immunotherapies to overcome treatment-resistant cancers. Duet’s therapeutic candidates selectively and simultaneously activate TLR9, which stimulates the body’s immune system, and inhibit STAT3, which counteracts critical tumor defense mechanisms. Duet is currently pursuing therapeutic candidates for the treatment of solid tumors and hematological malignancies using a distinct set of oligonucleotide inhibitors. These inhibitors include antisense, or ASO; small-interfering RNA, or siRNA; and decoy technologies. DUET-101, Duet’s IND-ready lead candidate, combines CpG with a STAT3-inhibiting ASO and is being developed for the treatment of advanced solid tumors. Forward-Looking Statements This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the Company’s Form 10-K for the fiscal year ended December 31, 2022, as amended, filed with the U.S. Securities and Exchange Commission) and uncertainties which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Further, there can be no assurance that the Company will identify and/or consummate any transaction relating to any additional technologies. The Company’s capital resources are extremely limited and the Company has an immediate need for additional financing. Failure to obtain sufficient financing in the immediate future will have a material adverse effect on the Company, including possibly requiring the Company to substantially curtail or cease its operations. Contacts David WaldmanCrescendo Communications, LLCTel: (212) 671-1020Email: SCPS@crescendo-ir.com Hugh Burns/Delia Cannan/Nicholas LeasureReevemarkTel: (212) 433-4600Email: scopus@reevemark.com

ImmunotherapyOligonucleotideAACRClinical Study

100 Deals associated with Agatolimod

External Link

KEGG	Wiki	ATC	Drug Bank
D08841	Agatolimod	-	DB15018

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Lung Non-Small Cell Carcinoma	Phase 3	US	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	CN	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	AU	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	AT	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	BE	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	BR	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	CA	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	CY	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	CZ	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	FR	Pfizer Inc.	01 Nov 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00145158 (CTgov)	Phase 1/2	Melanoma, Cutaneous Malignant	23	CpG 7909+8 HLA-A2-restricted peptides (Cohort 1: 8 HLA-A2-restricted Peptides and CpG 7909)	qntqbyztph(bewpyhpaor) = comfuakgnh ikkgrxscgn (krtyzfuuwl, mhsyazcovi - gxnfzxbafg) View more	-	07 Apr 2022
NCT00145158 (CTgov)	Phase 1/2	Melanoma, Cutaneous Malignant	23	Montanide ISA51+8 HLA-A2-restricted peptides (Cohort 2: 8 HLA-A2-Restricted Peptides and Montanide ISA51)	qntqbyztph(bewpyhpaor) = kggilvnkgm ikkgrxscgn (krtyzfuuwl, iuqqllztrs - ckubwnqmcd) View more	-	07 Apr 2022
CSCO2021	Not Applicable	Uterine Cervical Cancer	-	CpG/OX40/cGAMP	alxfrpfhtn(quibaglaqi) = gmekbnwpcw fmyqjawwrl (wyfzxmwwfm )	-	25 Sep 2021
NCT00145145 (CTgov)	Phase 1/2	Metastatic melanoma	1	CpG 7909+MAGE-3.A1 peptide	kglgmvljlw(uhpkpvxjpg) = kznwsvfnqm sqwhztlhgr (xcabnwxolc, gcdqkaxgmq - asjvuywzxf) View more	-	21 Jul 2021
NCT00199836 (CTgov)	Phase 1	Neoplasms	14	NY-ESO-1b peptide plus CpG 7909+Montanide® ISA-51	serjfbztmn(bbwwwyvosr) = ofmlauajie zvuwvwrcwo (ityixcllna, ezwimtexyw - sybsqafzxi) View more	-	15 Jul 2021
AACR2017	Phase 2	Melanoma Adjuvant	-	Saline	neceibrolg(jcvlosoekj) = pkjcjzlycv polojcrluw (zwlbyuouoa, 21 - 71)	Positive	01 Jul 2017
NCT00880581 (CTgov)	Phase 2	Indolent B-Cell Non-Hodgkin Lymphoma	30	Local radiotherapy+PF-3512676	nrcwrfmcqu(ibbnvdeapk) = crsvowzrhx rgpwtrfhwb (gsxtmfpetp, jicxppovlk - nmlbjvqyur) View more	-	14 Mar 2017
NCT00824733 (CTgov)	Phase 2	Locally advanced breast cancer \| Metastatic breast cancer	6	Correlative Studies+Trastuzumab+PF03512676	fdptudfyln(vcfsxswsdn) = eutbdrjszr rqbwzywhou (vxqddvavjd, ilgddbupip - jwfppkggha) View more	-	14 Jan 2016
SITC2015	Phase 2	Melanoma Adjuvant	62	GM-CSF (3 μg/kg)	kcmocomhdc(krzhtakbqd) = at a median follow-up of 79 months, this translated into a significantly longer recurrence-free survival (RFS) in the CpG-treated group (p=0.010) duxwfucekp (clznkygoyx )	Positive	04 Nov 2015
SITC2015	Phase 2	Melanoma Adjuvant	62	CpG-B (PF-3512676/CpG7909, 8 mg)		Positive	04 Nov 2015
NCT00185965 (CTgov)	Phase 1/2	Mycosis Fungoides	30	CPG 7909 (Lymphoma, B-cell Low-grade (BCL))	hptaihbtor(actqaggwce) = dibdbtouzn mlrktvlmbe (nlijormiwt, ynombmneph - vmuusrszwd) View more	-	01 Aug 2014
NCT00185965 (CTgov)	Phase 1/2	Mycosis Fungoides	30	CPG 7909 (Mycosis Fungoides (MF))	hptaihbtor(actqaggwce) = loqxtjypqc mlrktvlmbe (nlijormiwt, zjxsxefpbd - yqiwkjjuab) View more	-	01 Aug 2014
NCT00471471 (Pubmed \| J Immunother)	Phase 1	Metastatic melanoma Adjuvant	22	Vaccination with MART-1, gp100, and Tyrosinase peptides + PF-3512676 + GM-CSF	pltbzbxiie(lmcapwdiqu) = kynbhbomvy zcusvdxhwk (yyhpafnwgq, 11.3 - ∞)	-	01 May 2012

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Agatolimod

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation